This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in the Cards for Teva (TEVA) This Earnings Season?
by Zacks Equity Research
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q3 sales
Teva Pharmaceutical Industries Ltd. (TEVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.15 in the latest trading session, marking a -0.49% move from the prior day.
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $8.03, moving -1.65% from the previous trading session.
Lannett (LCI) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Lannet's (LCI) fiscal first-quarter 2020 results are likely to reflect strong performance of its anti-psychosis and cardiovascular drugs.
Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Lilly (LLY) Q3 Earnings Top Estimates, Sales Lag, Stock Down
by Zacks Equity Research
Eli Lilly's (LLY) Q3 earnings beat estimates while sales miss. Shares drop in pre-market trading.
J&J (JNJ) Recalls Baby Powder Batch as FDA Finds Asbestos
by Zacks Equity Research
J&J (JNJ) voluntarily recalls one lot of its baby powders, which is the subject of numerous lawsuits claiming that its talc-based products contain asbestos that causes cancer.
Q3 Earnings Reports to Flood Wall Street This Week
by Zacks Equity Research
Q3 Earnings Reports to Flood Wall Street This Week
Opioid Settlement, Boeing Downgrades: Markets Looking Up
by Mark Vickery
Futures are up somewhat in this Monday's pre-market after a sell-off Friday. Much of the sentiment going forward will rely on Q3 results and other news items.
J&J (JNJ) Beats on Q3 Earnings as Sales Rise, Ups 2019 View
by Zacks Equity Research
J&J (JNJ) comes up with encouraging third-quarter 2019 results.
Lilly Gets FDA Approval for New Oral Tablets for Migraine
by Zacks Equity Research
Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.
Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry
by Zacks Equity Research
Emergent's (EBS) vaccine portfolio holds great potential with the newly-acquired Narcan nasal spray progressing well. Severe rivalry remains a concern though.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $6.98 in the latest trading session, marking a +0.14% move from the prior day.
AstraZeneca's Fasenra Gets FDA Nod for Self-Administration
by Zacks Equity Research
The FDA approval of the self-administration option and auto-injector of AstraZeneca's (AZN) Fasenra is supported by data from the phase III GRECO study and the phase I AMES study
Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down
by Zacks Equity Research
Bausch's (BHC) shares down on lawsuit filed against Novartis' Sandoz defending Xifaxan patents.
Teva Pharmaceutical Industries Ltd. (TEVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $6.76 in the latest trading session, marking a -1.74% move from the prior day.
Mallinckrodt Up on Settlement Agreement With Ohio Counties
by Zacks Equity Research
Mallinckrodt (MNK) gains on the execution of a settlement agreement with Cuyahoga and Summit Counties in Ohio concerning the lawsuits pending in MDL.
Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen
by Zacks Equity Research
Mylan (MYL) sinks after the SEC charges it for misclassification of EpiPen.
Opioid Overdose Crisis in US Likely to Affect These 3 Stocks
by Sreyoshi Mukherjee
Increasing lawsuits against pharmaceutical companies are likely to impact retailers and distributors.
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $6.96 in the latest trading session, marking a -1.14% move from the prior day.
Mallinckrodt's StrataGraft Tissue Phase III Data Positive
by Zacks Equity Research
Mallinckrodt's (MNK) experimental StrataGraft regenerative tissue meets goals in a late-stage study for the treatment of burns.
J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use
by Zacks Equity Research
J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $8.04, moving +1.26% from the previous trading session.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Apple, American Express, Kraft Heinz and Teva Pharmaceutical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Apple, American Express, Kraft Heinz and Teva Pharmaceutical
Buffett's Best & Worst Performing Stocks Thus Far in 2019
by Tirthankar Chakraborty
So far this year, here are the winners and losers of Oracle of Omaha's favored companies.